Amgen Inc. Derivative Liability
Amgen Inc. (AMGN) had Derivative Liability of $1.31 billion as of 2023-09-30, per its 10-Q filed 2023-10-31.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2023-10-31
- 2023-09-30: Derivative Liability $1.31B.
- 2023-06-30: Derivative Liability $1.31B.
- 2023-03-31: Derivative Liability $1.25B.
- 2022-12-31: Derivative Liability $1.40B.
| Period end | Derivative Liability |
|---|---|
| 2023-09-30 | $1.31B 10-Q · filed 2023-10-31 |
| 2023-06-30 | $1.31B 10-Q · filed 2023-08-04 |
| 2023-03-31 | $1.25B 10-Q · filed 2023-04-28 |
| 2022-12-31 | $1.40B 10-Q · filed 2023-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |